Nass Valley Announces Changes to Board of Directors
Trading Symbols
CSE: NVG
Deutsche Borse, Frankfurt: 3NVN
Germany: WKN A1JVHM/
ISIN CA6315202029
www.nassvalleygateway.com
VANCOUVER, May 2, 2019 /CNW/ - Nass Valley Gateway Ltd. (the "Company" or "Nass Valley"), announces that it has accepted the resignation of Dr. Samuel Alawieh as Director and COO of the Company and its Subsidiary Advanced Bioceuticals Limited ("ABL") for personal reasons, effective April 26, 2019. Nass Valley acknowledges Dr. Alawieh's contributions especially in ABL and wishes him the best with his future endeavours.
Nass Valley also wishes to announce the planned resignation of Milo Filgas as Director of the Company and its Audit Committee. Mr. Filgas' resignation is conditional upon the CSE acceptance of the "Personal Information Form" submitted by the newly nominated board member and highly qualified independent member of the Audit Committee. The Company would also thank Mr. Filgas for his contributions and is looking forward to continue working with him as a member of its Advisory Committee.
The Company's President and CEO, Mr. John Peter Affenita commented, "We will announce the new appointments to the Board very shortly and I am convinced that with the industry leading knowledge of its new team members Nass Valley will be well positioned to meet the challenges of its planned vertical integration within the CBD sector and the growing needs of our customers".
ABOUT NASS VALLEY
Nass Valley Gateway (CSE: "NVG"; Frankfurt: "3NVN") is a diversified healthcare company which is focused to further expand the business of its acquired subsidiary Pro-Thotics Technology Inc. ("PTI") which was established in 1988. The Company is increasing its marketing of durable medical equipment products (DME-Business) on a national level, to encompass all states of the USA and other areas of North America and is aggressively developing the marketing, production and vertical integration of Cannabidiol (CBD) products without Tetrahydrocannabinol ("THC") content for internal use including CBD infused skin, bath, and body care products of its wholly owned subsidiary Advanced Bioceuticals Limited ("ABL").
PTI is licensed to supply its products also to Medicare patients in the US and has established, over its more than 25 -year history, a database of more than 200,000 patients, located throughout the U.S. and Puerto Rico, who were seeking wellness from pain relief.
Through its subsidiary ABL, Nass Valley is determined to expand upon this pain relief concept tof its ABL-Business and to aggressively focus on the hemp-based CBD marketplace with a global market of $3.1 billion (New Frontier Data) and expand its current New Jersey operations internationally.
Neither the CSE nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of the contents of this news release.
We seek Safe Harbor.
SOURCE Nass Valley Gateway Ltd.
please contact: John Affenita, President & CEO; ph: +1 (516) 680-0433 or +1.604-617-6794
Share this article